MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress

On May 12, 2022 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, reported that two abstracts highlighting data and information for zandelisib, an investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies, will be presented at the upcoming European Hematology Association (EHA) (Free EHA Whitepaper) 2022 Hybrid Congress to be held June 9 – 17, 2022 (Press release, Kyowa Hakko Kirin, MAY 12, 2022, View Source [SID1234614315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Title: Efficacy and Safety of Zandelisib Administered by Intermittent Dosing (ID) in Patients with Relapsed or Refractory (r/r) Follicular Lymphoma: Primary Analysis of the Global Phase 2 Study TIDAL
Session Title: Indolent & mantle cell non-Hodgkin lymphoma – Clinical
Presenter: Andrew David Zelenetz, PhD, MD
Time: June 11, 11:30am-12:45pm CEST
Abstract Code: S208

Poster Title: Zandelisib on Intermittent Dosing as a Single Agent or in Combination with Rituximab or Zanubrutinib in Relapsed or Refractory (r/r) Follicular Lymphoma (FL): Results from a Multi-Arm Phase 1b Study
Session Title: Indolent & mantle cell non-Hodgkin lymphoma – Clinical
Time: June 10, 2:30pm-3:45pm CEST
Presenter: Jacob Drobnyk Soumerai, MD
Abstract Code: P1114

The abstracts are available on the EHA (Free EHA Whitepaper) Annual Congress website. All presentations will be made available on the EHA (Free EHA Whitepaper) website for on-demand viewing on June 10, 2022.